Think Bioscience

Think Bioscience is a private, preclinical-stage biotechnology company pioneering a novel approach to drug discovery by applying synthetic biology to identify and drug 'undruggable' targets. The company has developed a proprietary platform that uses engineered microbes to find functional, ligandable pockets on proteins, enabling the discovery of new small-molecule therapeutics. Since its founding, Think has secured significant non-dilutive grant funding and completed an oversubscribed $55M Series A round in early 2026 to accelerate its platform and pipeline. The company is building a strong leadership team and scientific advisory board with deep drug discovery expertise.

Uses synthetic biology to engineer microbes as discovery engines to identify novel, functional binding pockets ('pocket-finding') and small-molecule mechanisms of action for historically challenging drug targets.

Competes in the broad 'drugging the undruggable' space against companies using targeted protein degradation, covalent chemistry, allosteric inhibition, and macrocyclic peptides. Think's differentiation is its use of synthetic biology and cellular context for empirical, function-based discovery of novel pockets and mechanisms.